iMBIORAY
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
iMBIORAY - overview
Established
2014
Location
Hangzhou, Zhejiang, China
Primary Industry
Biotechnology
About
Established in 2014 and based in Hangzhou, China, iMBIORAY (Hangzhou) Biopharmaceutical Co. , Ltd. , trading under the name iMBIORAY, operates as a medical company that focuses on the research and development of tumor drugs. Zhenwei Miao, the founder and CEO of the company, once served as chief scientist of Enanta and senior chemical director of Ambrx.
In February 2026, the firm raised CNY 200 million in series B funding. The company provides cancer and immune diseases treatment, and tumor cell immunotherapy drug. The company focuses on CAR-NK cell therapy, bispecific antibodies and AIC drugs R&D. The company develops bispecific antibody technology and antibody conjugation (ADC) technology.
The company's products include CAR-raNK IBR733 and IBR854, and tiNK cell therapy. Products can be used in tumor immunotherapy, immune diseases, chronic diseases and CNS diseases. The company’s revenue is generated by the development and potential licensing of immunotherapy drug candidates and cell therapy platforms. It also earns income through strategic research collaborations and partnerships with other pharmaceutical entities to co-develop bispecific antibodies and antibody-drug conjugate (ADC) technologies.
The company plans to use the series B funding to accelerate the clinical development of its core products, expand its large-scale manufacturing capacity, and strengthen its commercial layout.
Current Investors
South China Venture Capital, Zhuhai Longmen Capital Management, Shenzhen Lucky Source Investment Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Healthcare, Pharmaceuticals
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
iMBIORAY - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.